Zymeworks Inc. (ZYME) is a publicly traded Healthcare sector company. As of May 20, 2026, ZYME trades at $24.98 with a market cap of $1.80B and a P/E ratio of -6.10. ZYME moved +1.86% today. Year to date, ZYME is -2.51%; over the trailing twelve months it is +99.84%. Its 52-week range spans $9.03 to $29.75. Analyst consensus is strong buy with an average price target of $39.89. Rallies surfaces ZYME's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Zymeworks ZW191 Achieves 61% ORR and 7.6-Month PFS in Phase 1: Phase 1 data for Zymeworks’ ZW191 shows a confirmed objective response rate of 61% at 6.4–9.6 mg/kg in platinum-resistant ovarian cancer and a median progression-free survival of 7.6 months across ovarian and endometrial cohorts. The trial reported manageable safety with 55% grade ≥3 treatment-emergent adverse events and no unexpected signals.
| Metric | Value |
|---|---|
| Price | $24.98 |
| Market Cap | $1.80B |
| P/E Ratio | -6.10 |
| EPS | $-4.08 |
| Dividend Yield | 0.00% |
| 52-Week High | $29.75 |
| 52-Week Low | $9.03 |
| Volume | 429.52K |
| Avg Volume | 0 |
| Revenue (TTM) | $31.62M |
| Net Income | $-236.97M |
| Gross Margin | 0.00% |
11 analysts cover ZYME: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.89.